Literature DB >> 19909598

Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment.

Gabriella Garruti1, Raffaella Depalo, Maria Grazia Vita, Filomenamila Lorusso, Federica Giampetruzzi, Aurelia Bellomo Damato, Francesco Giorgino.   

Abstract

In the last few years, polycystic ovary syndrome (PCOS) has deserved major attention because it is linked to the same cluster of events that promote the metabolic syndrome. This review will point out the relationships between fat excess, insulin resistance and the metabolic syndrome. Adipocytes are actually considered as endocrine cells that synthesize and release molecules (adipokines) that play an endocrine/paracrine role, such as adiponectin, atrial natriuretic peptide, leptin, resistin, tumour necrosis factor alpha (TNFalpha). Metabolic syndrome is a chronic low-grade inflammatory condition in which adipokines play a major role. Isolated adipocytes from women with PCOS express higher mRNA concentrations of some adipokines involved in cardiovascular risk and insulin resistance. However, environmental factors and lifestyle play a major role in determining the appearance of the phenotypes of PCOS. In morbid obese women with PCOS, bariatric surgery decreases bodyweight and fat excess and reverses hyperandrogenism and sterility. In lean or overweight women with PCOS, changes in lifestyle in combination with drugs reducing visceral fat and insulin resistance reverse the symptoms and signs of PCOS. Promising treatments for PCOS seem to be insulin sensitizers such as metformin and glitazones.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909598     DOI: 10.1016/j.rbmo.2009.05.010

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  24 in total

1.  Defining the role of bariatric surgery in polycystic ovarian syndrome patients.

Authors:  Shaveta M Malik; Michael L Traub
Journal:  World J Diabetes       Date:  2012-04-15

2.  Patterns of Bariatric Surgeries Among U.S. Women Diagnosed with Polycystic Ovarian Syndrome.

Authors:  Hind A Beydoun; May A Beydoun; Sharmin Hossain; Laurel Stadtmauer; Shaker M Eid; Alan B Zonderman
Journal:  J Womens Health (Larchmt)       Date:  2020-02-20       Impact factor: 2.681

Review 3.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

4.  Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States.

Authors:  Hind A Beydoun; May A Beydoun; Natasha Wiggins; Laurel Stadtmauer
Journal:  Maturitas       Date:  2011-11-15       Impact factor: 4.342

5.  Assessing and treating insulin resistance in women with polycystic ovarian syndrome.

Authors:  Michael L Traub
Journal:  World J Diabetes       Date:  2011-03-15

6.  Cardiac fatty acid uptake and metabolism in the rat model of polycystic ovary syndrome.

Authors:  Snežana Tepavčević; Danijela Vojnović Milutinović; Djuro Macut; Mojca Stojiljković; Marina Nikolić; Ivana Božić-Antić; Tijana Ćulafić; Jelica Bjekić-Macut; Gordana Matić; Goran Korićanac
Journal:  Endocrine       Date:  2015-02-22       Impact factor: 3.633

7.  Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case-control study.

Authors:  Jayeon Kim; Jennifer E Mersereau; Nikhil Khankari; Patrick T Bradshaw; Lauren E McCullough; Rebecca Cleveland; Sumitra Shantakumar; Susan L Teitelbuam; Alfred I Neugut; Ruby T Senie; Marilie D Gammon
Journal:  Cancer Causes Control       Date:  2016-01-21       Impact factor: 2.506

8.  IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance.

Authors:  Anna M Fulghesu; Francesca Sanna; Sabrina Uda; Roberta Magnini; Elaine Portoghese; Barbara Batetta
Journal:  Mediators Inflamm       Date:  2011-03-20       Impact factor: 4.711

9.  Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-α and interleukin-6 in patients with polycystic ovary syndrome.

Authors:  Chung-Hoon Kim; Jun-Woo Ahn; Rae-Mi You; Sung-Hoon Kim; Hee-Dong Chae; Byung-Moon Kang
Journal:  Clin Exp Reprod Med       Date:  2011-06-30

10.  The effects of modified alternate-day fasting diet on weight loss and CAD risk factors in overweight and obese women.

Authors:  Samira Eshghinia; Fatemeh Mohammadzadeh
Journal:  J Diabetes Metab Disord       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.